OpenAI Researcher Miles Wang Plans AI Drug Discovery Startup Valued at $2B
OpenAI researcher Miles Wang is reportedly in talks to launch a new artificial intelligence startup focused on drug discovery. The company is said to be seeking a $2 billion valuation.
Miles Wang, a researcher at OpenAI known for his work applying AI to accelerate scientific and biological discovery, is preparing to launch a new startup. The venture will focus on developing AI models for drug discovery, according to sources with knowledge of the plans. Several other OpenAI researchers are expected to join Wang in the new company.
Wang is reportedly in discussions to raise approximately $200 million in funding, with the startup potentially valued at $2 billion. Lightspeed is cited as being in talks to lead this funding round. These discussions are ongoing, and the final details of the deal are subject to change.
The reported funding talks highlight investor interest in leveraging AI for advancements in the life sciences sector. This trend sees significant capital flowing into companies aiming to use artificial intelligence to streamline the identification of new drugs and understand complex molecular interactions.
While Wang has disputed the reported funding figures and company description, he has not provided specific corrected details. Lightspeed has not yet responded to requests for comment.